ReviewBiochemia medica2013
Copeptin and its potential role in diagnosis and prognosis of various diseases.
Review in Biochemia medica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Pooled it
- Efficacy of blood copeptin level for the prediction of mortality of adult patients with sepsis: a meta-analysis.Frontiers in medicine · 2025Pooled it
- Copeptin as biomarker for acute ischemic stroke prognosis and revascularization treatment efficacy.Frontiers in neurology · 2024Pooled it
- Trial
- The role of biomarkers across the care continuum in acute heart failure.Biomarker research · 2026Review
- Novel biomarkers to guide glucocorticoid replacement in primary adrenal insufficiency: a proof-of-concept study using copeptin-derived ratios.Journal of endocrinological investigation · 2026Article
- Copeptin, Routine Laboratory Parameters, and Ischemic Etiology of Heart Failure Predict Outcomes in Elderly Patients with Decompensated Heart Failure.Biomedicines · 2025Article
- Association of serum copeptin levels with pulmonary complications and heart right ventricular functions in common variable immunodeficiency.BMC immunology · 2025Article
- Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases.World journal of cardiology · 2025Review
- Copeptin as a New Blood-Based Marker for Differential Diagnosis in Stroke Patients.International journal of molecular sciences · 2025Review
- Copeptin Hormone Concentrations in Dogs with Heart Disease and Relationship with Antidiuretic Hormone.Animals : an open access journal from MDPI · 2025Article
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Prognostic role of serum copeptin levels in adults with graded traumatic brain injury.Irish journal of medical science · 2025Article
- Relationship between serum copeptin levels and non-invasive endothelial function indicators in dipper and non-dipper hypertensive patients.American journal of cardiovascular disease · 2025Article
- A New Biomarker Copeptin in Determining Disease Severity in COVID-19.Infectious diseases & clinical microbiology · 2024Article
- Article
- Copeptin: a novel prognostic biomarker in trauma: a review article.Journal of health, population, and nutrition · 2023Review
- Review novel insights into the diagnostic and prognostic function of copeptin in daily clinical practice.Molecular biology reports · 2023Review
- Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.Frontiers in pediatrics · 2023Review
- Copeptin as a Biomarker of Microcirculation Alterations in Systemic Sclerosis.Clinical, cosmetic and investigational dermatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The need for faster diagnosis, more accurate prognostic assessment and treatment decisions in various diseases has lead to the investigations of new biomarkers. The hope is that this new biomarkers will enable early decision making in clinical practice. Arginine vasopressin (AVP) is one of the main hormones of the hypothalamic-pituitary-adrenal axis. Its main stimulus for secretion is hyperosmolarity, but AVP system is also stimulated by exposure of the body to endogenous stress. Reliable measurement of AVP concentration is difficult because it is subject to preanalytical and analytical errors. It is therefore not used in clinical practice. Copeptin, a 39-aminoacid glycopeptide, is a C-terminal part of the precursor pre-provasopressin (pre-proAVP). Activation of AVP system stimulates copeptin secretion into the circulation from the posterior pituitary gland in equimolar amounts with AVP. Therefore, copeptin directly reflects AVP concentration and can be used as surrogate biomarker of AVP secretion. Even mild to moderate stress situations contribute to release of copeptin. These reasons have lead to a handful of research on copeptin in various diseases. This review summarizes the current achievements in the research of copeptin as a diagnostic and prognostic marker and also discusses its association in different disease processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.